Navigation Links
PharmAthene to Host a Conference Call and Webcast on Wednesday, April 29th at 4:30 PM to Provide an Update on the SparVax(TM) rPA Anthrax Vaccine Program
Date:4/28/2009

ANNAPOLIS, Md., April 28 /PRNewswire-FirstCall/ -- PharmAthene, Inc. (NYSE Amex: PIP) a biodefense company developing medical countermeasures against biological and chemical threats, announced today that it will be hosting a conference call for investors on Wednesday, April 29th beginning at 4:30 p.m. E.T., to review the status of its rPA anthrax vaccine program.

The dial-in number within the United States is 866-788-0540. The dial-in number for international callers is 857-350-1678. The participant passcode is 82129094.

A replay of the conference call will be available for 30 days, beginning at approximately 7:30 p.m. Eastern Time on Wednesday, April 29, 2009 until approximately 11:59 p.m. Eastern Time on May 29, 2009. The dial-in number from within the United States is 888-286-8010. For international callers, the dial-in number is 617-801-6888. The participant passcode is 53903666.

The conference call will also be webcast and can be accessed from the company's website at www.pharmathene.com. A link to the webcast may be found on the Investor Relations section of the website.

About PharmAthene, Inc.

PharmAthene was formed to meet the critical needs of the United States and its allies by developing and commercializing medical countermeasures against biological and chemical weapons. PharmAthene's lead product development programs include:

  • SparVax(TM) - a second generation recombinant protective antigen (rPA) anthrax vaccine
  • Third generation rPA anthrax vaccine
  • Valortim(R) - a fully human monoclonal antibody for the prevention and treatment of anthrax infection
  • Protexia(R) - a novel bioscavenger for the prevention and treatm
    '/>"/>

SOURCE PharmAthene, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. PharmAthene Initiates Phase I Clinical Trial of Nerve Agent Bioscavenger Protexia(R)
2. PharmAthene Presents Data for Protexia(R) and Valortim(R) at 2008 BARDA Industry Conference / PHEMCE Stakeholders Workshop
3. PharmAthenes Recombinant Butyrylcholinesterase (rBChE) May Play A Neuroprotective Role in Alzheimers Disease
4. PharmAthene to Webcast its Third Quarter Conference Call on November 13, 2007 at 4:30 P.M. Eastern Time
5. MedNet Solutions to Share Industry Expertise at the 13th Annual EDC & Beyond Conference in Orlando, FL
6. Progress Against Malaria and Other Infectious Diseases Among Highlights at Annual Vaccine Conference
7. Karmanos Cancer Institute Researchers Present Breast Cancer Advancements at Conference
8. Dendreon to Hold a Conference Call Tomorrow at 9:00 AM ET to Discuss Final Results of Phase 3 PROVENGE IMPACT Trial
9. NewCardio Leadership to Present Two Abstracts at ISCE Conference
10. Arena Pharmaceuticals to Host Conference Call and Webcast on Monday, March 30, 2009 to Discuss Lorcaserin Pivotal Phase 3 Obesity Trial Results
11. ULURU Inc. to Present Altrazeal(TM) Clinical Evidence and Advanced Therapeutic Research at the Diabetic Foot Global Conference (DFCon) 2009

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)... The Netherlands and JOHANNESBURG, November 25 /PR...sion and Pyxis Discovery announced today,that they...market both,companies, services. , Pyxis,...covery expertise,will be coupled with iThemba,s se...chemistry support to projects identified through P...
(Date:11/24/2009)...Nov. 24 ,, WHAT: Rom Houbens,... years following an auto accident, was actually fu...he subject of a Good Morning America segment. The...ustrate how people with Locked-in Syndrome and oth...: Good Morning America -- Tuesday, November 24 ...
(Date:11/24/2009)...v. 24 Anadys Pharmaceuti...t will present at the 21st Annual Piper Jaffray He...t 9:00 a.m. EST (6:00 a.m. PST). The conference i...Worland, Ph.D., President and Chief Executive Offi...and its clinical development programs, ANA598 and ...
Breaking Medicine Technology:iThemba Pharmaceuticals (Pty) Ltd and Pyxis Discovery B.V. Announce Collaborative Agreement to Offer a Combined Service Offering 2DynaVox EyeMax Featured in Good Morning America Segment About Man Thought To Be in Coma for 23 Years 2Anadys Pharmaceuticals to Present at the Piper Jaffray Healthcare Conference 2Cardium Announces Commercial Development of Excellagen 28TM 29 a Customized Collagen Based Topical Gel for Initial Use as an Adjunct to Surgical Debri 59439 1Cardium Announces Commercial Development of Excellagen 28TM 29 a Customized Collagen Based Topical Gel for Initial Use as an Adjunct to Surgical Debri 59439 2Cardium Announces Commercial Development of Excellagen 28TM 29 a Customized Collagen Based Topical Gel for Initial Use as an Adjunct to Surgical Debri 59439 3Cardium Announces Commercial Development of Excellagen 28TM 29 a Customized Collagen Based Topical Gel for Initial Use as an Adjunct to Surgical Debri 59439 4Cardium Announces Commercial Development of Excellagen 28TM 29 a Customized Collagen Based Topical Gel for Initial Use as an Adjunct to Surgical Debri 59439 5Cardium Announces Commercial Development of Excellagen 28TM 29 a Customized Collagen Based Topical Gel for Initial Use as an Adjunct to Surgical Debri 59439 6Cardium Announces Commercial Development of Excellagen 28TM 29 a Customized Collagen Based Topical Gel for Initial Use as an Adjunct to Surgical Debri 59439 7Cardium Announces Commercial Development of Excellagen 28TM 29 a Customized Collagen Based Topical Gel for Initial Use as an Adjunct to Surgical Debri 59439 8Eastern Europes First Novalis Tx 28TM 29 Radiosurgery Platform Begins Radiotherapy Treatments in Latvia using RapidArc 28R 29 Technology 5467 1Eastern Europes First Novalis Tx 28TM 29 Radiosurgery Platform Begins Radiotherapy Treatments in Latvia using RapidArc 28R 29 Technology 5467 2Eastern Europes First Novalis Tx 28TM 29 Radiosurgery Platform Begins Radiotherapy Treatments in Latvia using RapidArc 28R 29 Technology 5467 3Baxa Announces IntelliFlowRx 28TM 29 to Become DoseEdge 28TM 29 Dose Management System 5463 1Baxa Announces IntelliFlowRx 28TM 29 to Become DoseEdge 28TM 29 Dose Management System 5463 2
... Pa., Sept. 19 Wyeth,Pharmaceuticals, a division ...Phase 3 fracture data for bazedoxifene, a selectiv...iety for Bone and Mineral Research Annual,Meeting....ene 20 mg and 40,mg significantly reduced the rela... and 37 percent, respectively, compared with place...
...pt. 19 Alba Therapeutics Corporation today,announ...eek Phase IIb trial,with oral AT-1001, an inhibito...maintenance of remission in patients with Celiac D...bo-controlled, dose ranging study will,evaluate th...CD subjects,during a six-week gluten challenge, wh...
Other Medicine Technology:Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis 2Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis 3Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis 4Alba Therapeutics Announces Phase IIb Clinical Trial for Oral AT-1001 for the Treatment of Celiac Disease 2
(Date:11/26/2009)...25 years, the number of Americans living with diab...ion in 2009 to 44.1 million in 2034. Over the same...rising from $113 billion to $336 billion, even wit...chers based at the University of Chicago report in...mber of those with diabetes covered by Medicare wi...
(Date:11/26/2009)...ger thrill when on an emotional rollercoaster, stu...y News) -- Call it the fear factor meets the jubil...ctators -- especially those who root for the winni... a closely contested match and victory was in doub..., Chew on that this Thanksgiving weekend as you,...
(Date:11/26/2009)... Research Triangle Dental (RTDental), a...rolina, today announced the expansion of its servi...entist, Dr. Doug Macmillan. , ...ntal is pleased to announce that Dr. Doug Macmilla...mpleted an additional advanced training seminar. ...
(Date:11/25/2009)...INA, Minn., Nov. 25 Whe...their dentist. But a chiropractor can also give p...poral-Mandibular Joint, which is where your jaw (m...al bone). ,, The most common symptoms associat...cking or popping of the jaw. But many other sympt...
(Date:11/25/2009)...ORONTO and CALGARY, Nov. 25 /PRNewswire/ - Sentine...ic Resonance Imaging (MRI) coils and software and ...tware enabling technologies, have introduced a web...tion software. ,, This innovative interface is ...dical imaging offering in the market. Calgary Scie...
Breaking Medicine News(10 mins):Health News:Diabetes cases to double and costs to triple by 2034 2Health News:Diabetes cases to double and costs to triple by 2034 3Health News:Watching the Nail-Biting Big Game Hurts So Good 2Health News:Watching the Nail-Biting Big Game Hurts So Good 3Health News:Dr. Douglas Macmillan Now Providing LUMINEERS at Research Triangle Dental 2Health News:Sentinelle Medical Inc. Introduces Aegis(TM) Web Powered By Calgary Scientific's PureWeb Technology 2Health News:Sentinelle Medical Inc. Introduces Aegis(TM) Web Powered By Calgary Scientific's PureWeb Technology 3
...ead regions' in the brain that could be responsibl...by Karolina Kluk, a Cambridge University student. ...opment of individualized hearing aids for children...not be used with babies. The new electrophysiologi...
...nal examination of a child, to determine the locat...gn of abuse. // This was discussed in the American...in Seattle recently. Retina is a light sensiti...e. A wide variety of conditions such as falls...
...ecalled from the market as stated by the FDA due t...cans. // So this brand would not be sold in market...ant formula, Mead Johnson Nutritionals of EVANSVIL...company for the recall is public health concern. A...
...s, preventing the spread of the deadly virus H5N1,...he Eastern past of France. // The farm in Versaill...y turkeys, was just 200mts away from the lake wher...nion farm has got the bird-flu infection. Nearly 8...
... against indiscriminate antibiotic use, saying th...e prescribed inappropriately. //This issue figure...microbials annual scientific discussion meeting in...ncrease in drug-resistant infections. Prof Tur...
...e complication following coronary artery bypass gr...enon gas, a new study has found. // The results o...d in Anesthesiology journal. The researchers...lopment of new treatments for diseases associated ...
Other Medicine News:Health News:New Test Offers Hope in Effective Hearing Aid Design for Babies 2Health News:Retinal Hemorrhage: No More a Sure Sign of Child Abuse 2
...ion via the pelvic nerves has proven to be an effe.... Through the use of mild electrical stimulation, ...d to encourage urinary control and continence. Zyn... a tool to aid in the treatment and alleviate the ...
High Dose Rate (HDR) Treatment System
...r Template Set is the HDR solution which duplicate...e. The template set consists of a small grid style...s placed in a Stepper Holder with variable ultraso...ble for different ultrasound stepper devices. The ...
Disposable Template
Medicine Products: